コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 te the concurrent administration of low dose medroxyprogesterone acetate.
2 h 8-bromo-cyclic adenosine monophosphate and medroxyprogesterone acetate.
3 nsdermal estradiol, 100 micro g/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10
4 njugated equine estrogen 0.625 mg a day plus medroxyprogesterone acetate 2.5 mg a day increased the r
5 ted equine estrogens 0.625 mg (combined with medroxyprogesterone acetate 2.5 mg daily in five women w
8 l women, either alone or in combination with medroxyprogesterone acetate (2.5 mg daily) for one month
9 ted equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo.
10 ted equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo.
11 ed equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily or to placebo
12 o daily conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg) or placebo and docu
13 quine estrogens (0.625 mg/d [estrogen]) plus medroxyprogesterone acetate (2.5 mg/d [progestin]) (E +
14 onjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) if they had a ute
15 y conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate); 2) 20 mg lovastatin/day an
16 ne estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily; or 5) placebo
17 Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, daily in one tablet
18 conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (
19 Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in one tablet (n =
21 conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n =
22 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n =
23 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or identical plac
24 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill.
26 gated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45)
28 d serious adverse reactions to intramuscular medroxyprogesterone acetate, a drug that contains polyet
32 w a progestational contraceptive drug (depot medroxyprogesterone acetate) affects food intake, restin
34 a-dihydrotestosterone, 17 beta-estradiol, or medroxyprogesterone acetate, also inhibited LNCaP 104-R2
35 gnal transduction, was also synergistic with medroxyprogesterone acetate and E2, but induced signific
37 norethynodrel), hormone replacement therapy (medroxyprogesterone acetate), and high-dose progestin tr
39 in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively.
40 idence interval [CI], 1.7-12.2), use of depo-medroxyprogesterone acetate (aOR, 3.2; 95% CI, 1.3-7.7),
41 o++ +[3,4-f] quinoline) was more potent than medroxyprogesterone acetate at counterpoising the effect
42 deployed drug combination of bezafibrate and medroxyprogesterone acetate (BaP) has shown anti-leukaem
43 ural progesterone and the clinical progestin medroxyprogesterone acetate block estrogen neuroprotecti
45 ule) alone or administered sequentially with medroxyprogesterone acetate can slow the progression of
47 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group rece
49 deployed drug combination of bezafibrate and medroxyprogesterone acetate (designated BaP) has potent
50 le (control), estradiol (E2) with or without medroxyprogesterone acetate, dexamethasone (Dex), or Org
51 measurements indicated that the addition of medroxyprogesterone acetate did not affect MCP-1 output,
52 cycle affected energy intake and REE, depot medroxyprogesterone acetate did not alter energy intake
53 nt with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall r
55 he use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) at the time of HIV-1
57 The injectable hormonal contraceptive depo-medroxyprogesterone acetate (DMPA) has been associated w
59 of the progesterone (Pg) birth control depot medroxyprogesterone acetate (DMPA) increases a woman's r
61 y investigates the association between depot medroxyprogesterone acetate (DMPA) injectable contracept
64 es (COCs) or the injectable progestins depot-medroxyprogesterone acetate (DMPA) or norethisterone ena
65 ice were treated with vehicle, 2 mg of depot medroxyprogesterone acetate (DMPA), or 10 mg of DMPA eve
66 dress this discrepancy, we developed a Depot medroxyprogesterone acetate (DMPA)-treated cotton rat Si
67 evels in HIV-uninfected women who used depot medroxyprogesterone acetate (DMPA; n = 32), the levonorg
68 patch, contraceptive vaginal ring, and depot medroxyprogesterone acetate [DMPA] injection) in the ove
69 h vehicle control, estradiol (E(2)), or with medroxyprogesterone acetate +/- E(2) under hypoxic and n
70 gamma (IFN-gamma) reversed these effects and medroxyprogesterone acetate elicited further reversal.
71 eta-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group).
72 conjugated equine estrogens, with or without medroxyprogesterone acetate, focusing on health benefits
73 conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a
75 ther alone or with sequentially administered medroxyprogesterone acetate had no significant effect on
76 py of oestrogen with cyclic progestagen (eg. medroxyprogesterone acetate) had a relative risk of 14 (
77 with or without continuous administration of medroxyprogesterone acetate has failed to slow the progr
78 nt who is amenorrheic is currently receiving medroxyprogesterone acetate; her ultimate menstrual and
79 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1380)
80 of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, in 8506 women) or placebo (
81 er estrogen/progesterone oral combination or medroxyprogesterone acetate intramuscular) contraceptive
82 ), progestins and metabolites (progesterone, medroxyprogesterone acetate, megestrol acetate, mifepris
83 d equine estrogens (CEE) (0.625 mg/day) plus medroxyprogesterone acetate (MPA) (<10 mg/day) or oral C
86 d equine estrogens (CEE) 0.625 mg/d; CEE and medroxyprogesterone acetate (MPA) 10 mg on days 1 to 12
87 d equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily, in 16,60
90 n the presence of the hormonal contraceptive medroxyprogesterone acetate (MPA) and progesterone and t
91 ble with potent steroidal progestins such as medroxyprogesterone acetate (MPA) and trimegestone (TMG)
92 of three regimens of progestational agents: medroxyprogesterone acetate (MPA) at 2.5 mg daily (ie, c
93 ormation in animal models, and the progestin medroxyprogesterone acetate (MPA) blocks this effect.
94 dies indicate that the exogenous sex steroid medroxyprogesterone acetate (MPA) can impair cell-mediat
95 s of conjugated equine estrogens (CEEs) with medroxyprogesterone acetate (MPA) improve vasomotor symp
96 We found that treatment with the progestin medroxyprogesterone acetate (MPA) induced the expression
98 ated equine estrogen (CEE) alone or CEE plus medroxyprogesterone acetate (MPA)) on global cognitive f
99 ation of blood CD4+ T cells with TFV or TAF, Medroxyprogesterone acetate (MPA), but not Levonorgestre
100 ated equine estrogens (CEE), CEE plus cyclic medroxyprogesterone acetate (MPA), CEE plus daily MPA, a
101 rial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, ve
108 ated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) v
109 free medium with or without the progestogen, medroxyprogesterone acetate (MPA; 10(-6) M), using inter
110 ated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) o
113 in injured carotid arteries, (2) progestin (medroxyprogesterone acetate, MPA) blocks the vasoprotect
114 whereas combined estrogen plus a progestin (medroxyprogesterone acetate, MPA) HRT increases this ris
116 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1
117 conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380) or placebo (n = 1
118 5 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380), or placebo (n =
119 of conjugated equine estrogen with 2.5 mg of medroxyprogesterone acetate (n = 2145) or matching place
120 of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (n = 2229), or a matching pl
121 conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 8506) or placebo (n = 8
122 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 8506) or placebo (n = 8
123 5 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate (n=8506) or matching placebo
124 udy would merit complete withdrawal of depot medroxyprogesterone acetate needs to be balanced against
125 s significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-
128 ormone therapy with conjugated estrogens and medroxyprogesterone acetate or placebo and followed for
129 gen (conjugated equine oestrogens [CEE] plus medroxyprogesterone acetate) or placebo, and the other i
130 conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate, or placebo (n = 7,809), wit
133 Research suggests that Depo-Provera (depot medroxyprogesterone acetate; Pfizer, New York City, New
134 ease in HIV risk in the ten studies of depot medroxyprogesterone acetate (pooled hazard ratio [HR] 1.
136 We also report that synthetic progestin medroxyprogesterone acetate promotes regression of cance
137 estrogen, both alone and in combination with medroxyprogesterone acetate, reduced mean (+/-SD) plasma
138 strogen (estradiol, 1 mg/day) and progestin (medroxyprogesterone acetate) replacement therapy were co
139 ype of hormone used (ex. progesterone versus medroxyprogesterone acetate), the duration of the postme
140 7 days in either estradiol or estradiol plus medroxyprogesterone acetate to mimic the decidualizing s
141 ated with estradiol (E2; control) or with E2+medroxyprogesterone acetate (to mimic pregnancy)+/-throm
143 Treatment with oral conjugated estrogen plus medroxyprogesterone acetate was not associated with a si
144 gestogen contraceptives (IPCs), mostly depot medroxyprogesterone acetate, was 0.9 (95% confidence int
145 al tracts of Swiss Webster mice treated with medroxyprogesterone acetate were exposed in vivo to a 4%
146 of HIV acquisition for all women using depot medroxyprogesterone acetate, with a smaller increase in
147 5-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among wo
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。